

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-14. (Cancelled)

15. (Currently Amended) A compound, which is

- N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate;
- N-ethyl-N-(1-methyl-2-oxo-2-pyrid-3-ylethyl) 2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate;
- N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate;
- N-ethyl-N-(1-methyl-2-oxo-2-pyrid-2-ylethyl) 2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate; [[.]]
- N-[cyano(4-fluorophenyl)methyl]-N-phenyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-(α -cyanobenzyl)-N-ethyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- 2-{1-{4'-(trifluoromethyl)-1,1'-biphenyl-2-yl}carboxyl}piperid-4-yl}-1,3-thiazole-4-carboxylic acid;
- 1-(4-{4-(3-hydroxypiperid-1-yl)methanoyl}thiazol-2-yl)piperid-1-yl)-1-(4'-trifluoromethylbiphenyl-2-yl)methanone;
- N-methyl-N-(1-methyl-2-oxo-2-phenethyl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-methyl-N-(1-methyl-2-oxo-2(S)-phenethyl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-(7-oxo-7H-thieno[3,2-b]pyran-6-yl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-(2-methyl-4-oxo-4H-chromen-3-yl)-2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
- N-(α -cyanobenzyl)-N-isopropyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide; or

- N-[1-cyano-1-(pyrid-4-yl)methyl]-N-isopropyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide;
or a pharmaceutically acceptable salt thereof,
or an optical isomer thereof,
or an N-oxide or S-oxide oxidized form thereof .

16-18. (Cancelled)

19. (Previously Presented) A compound according to claim 15, which is N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate or a pharmaceutically acceptable salt thereof.

20. (Previously Presented) A compound according to claim 15, which is N-ethyl-N-(1-methyl-2-oxo-2-pyrid-3-ylethyl) 2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)-piperid-4-yl]thiazole-4-carbamate or a pharmaceutically acceptable salt thereof.

21. (Previously Presented) A compound according to claim 15, which is N-ethyl-N-(1-methyl-2-oxo-2-phenylethyl) 2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) A compound according to claim 15, which is N-ethyl-N-(1-methyl-2-oxo-2-pyrid-2-ylethyl) 2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carbamate or a pharmaceutically acceptable salt thereof.

23. (Previously Presented) A compound according to claim 15, which is N-[cyano(4-fluorophenyl)methyl]-N-phenyl-2-[1-(4'-trifluoromethyl-biphenyl-2-carbonyl)-piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) A compound according to claim 15, which is N-(α -cyanobenzyl)-N-ethyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

25. (Previously Presented) A compound according to claim 15, which is 2-

{1-{4'-(trifluoromethyl)-1,1'-biphenyl-2-yl]carboxyl}piperid-4-yl}-1,3-thiazole-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

26. (Previously Presented) A compound according to claim 15, which is 1-(4-{4-(3-hydroxypiperid-1-yl)methanoyl}thiazol-2-yl)piperid-1-yl)-1-(4'-trifluoromethylbiphenyl-2-yl)methanone or a pharmaceutically acceptable salt thereof.

27. (Previously Presented) A compound according to claim 15, which is N-methyl-N-(1-methyl-2-oxo-2-phenethyl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

28. (Previously Presented) A compound according to claim 15, which is N-methyl-N-(1-methyl-2-oxo-2(S)-phenethyl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

29. (Previously Presented) A compound according to claim 15, which is N-(7-oxo-7H-thieno[3,2-b]pyran-6-yl)-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

30. (Previously Presented) A compound according to claim 15, which is N-(2-methyl-4-oxo-4H-chromen-3-yl)-2-[1-(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

31. (Previously Presented) A compound according to claim 15, which is N-(α -cyanobenzyl)-N-isopropyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

32. (Previously Presented) A compound according to claim 15, which is N-[1-cyano-1-(pyrid-4-yl)methyl]-N-isopropyl-2-[1-(4'-trifluoromethylbiphenyl-2-carbonyl)piperid-4-yl]thiazole-4-carboxamide or a pharmaceutically acceptable salt thereof.

33. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 15 or a pharmaceutically acceptable salt thereof, or an optical

isomer thereof, or an oxidized form thereof and a pharmaceutically acceptable carrier.

34. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 19 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

35. (Previously Presented) A method for treating hypertriglyceridaemia, hypercholesterolaemia, or dyslipidaemia associated with diabetes, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 33.

36. (Currently Amended) A method for treating or preventing obesity, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 33.

37. (Previously Presented) A method for treating hypertriglyceridaemia, hypercholesterolaemia, or dyslipidaemia associated with diabetes, or for treating or preventing obesity, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 34.